Centessa Prescribed drugs Pronounces Addition of Harris L.

Centessa Prescribed drugs Pronounces Addition of Harris L.

BOSTON and LONDON, July 25, 2022 (GLOBE NEWSWIRE) — Centessa Prescribed drugs plc (Nasdaq: CNTA), a clinical-stage pharmaceutical firm with a Analysis & Improvement (R&D) innovation engine that goals to find, develop and finally ship impactful medicines to sufferers, in the present day introduced the appointment of Harris L. Rotman, PhD, as Senior Vice President, Regulatory Affairs.

“We’re more than happy to welcome Harris to our management crew as we put together for our SerpinPC program in Hemophilia B to maneuver into registrational research this 12 months and proceed to steadily advance our progressive uncommon illness and immuno-oncology pipeline,” stated Saurabh Saha, MD, PhD, Chief Government Officer of Centessa.

“I’m thrilled to affix the spectacular crew at Centessa,” stated Dr. Rotman. “This can be a uncommon alternative to affix an organization the place every program has the good thing about extraordinary R&D expertise and deep business expertise. I sit up for serving to advance Centessa’s compelling pipeline for sufferers with unmet wants.”

Previous to becoming a member of Centessa, Dr. Rotman served as Senior Vice President, Head of Regulatory Affairs at SwanBio Therapeutics, the place he was accountable for managing the corporate’s neuromuscular illness gene remedy packages. Dr. Rotman additionally beforehand served as Vice President, Head of Regulatory Affairs, Branded Enterprise at Endo Prescribed drugs the place he led the branded world regulatory affairs division within the US and Eire. Earlier in his profession, Dr. Rotman held government regulatory management roles with Indivior, Shire Prescribed drugs, Sanofi and Wyeth Prescribed drugs. Dr. Rotman earned his PhD in Microbiology and Molecular Virology from Thomas Jefferson College, and a BS in Organic Sciences from Cook dinner Faculty at Rutgers College.

About Centessa Prescribed drugs

Centessa Prescribed drugs plc is a clinical-stage pharmaceutical firm with an R&D innovation engine that goals to find, develop and finally ship impactful medicines to sufferers. Our packages span discovery-stage to late-stage improvement and canopy a spread of high-value indications in uncommon illnesses and immuno-oncology. We’re led by a administration crew with intensive R&D expertise, offering direct steerage to our program groups to quickly advance our candidates from analysis by all phases of improvement. For extra info, go to www.centessa.com, which doesn’t kind a part of this launch.

Ahead Trying Statements

This press launch comprises forward-looking statements. These statements could also be recognized by phrases equivalent to “could,” “may,” “will,” “may,” “would,” “ought to,” “anticipate,” “intend,” “plan,” “goal,” “anticipate,” “consider,” “estimate,” “predict,” “potential,” “proceed,” “ongoing,” “intention,” “search,” and variations of those phrases or related expressions which might be supposed to determine forward-looking statements. Any such statements on this press launch that aren’t statements of historic truth could also be deemed to be forward-looking statements, together with statements concerning the anticipated advantages of Dr. Rotman’s employment; statements regarding the prospects of our packages; statements associated to the Firm’s skill to develop our packages (together with our SerpinPC program) and ship impactful medicines to sufferers; the power of our key executives to drive execution of the Firm’s portfolio of packages; our asset-centric enterprise mannequin and the supposed benefits and advantages thereof; and analysis and medical improvement plans and the timing thereof. Any forward-looking statements on this press launch are based mostly on our present expectations, estimates and projections solely as of the date of this launch and are topic to plenty of dangers and uncertainties that might trigger precise outcomes to vary materially and adversely from these set forth in or implied by such forward-looking statements. These dangers and uncertainties embody, however usually are not restricted to, dangers associated to the protection and tolerability profile of our product candidates; our skill to guard and preserve our mental property place; enterprise (together with industrial viability), regulatory, financial and aggressive dangers, uncertainties, contingencies and assumptions concerning the Firm; dangers inherent in creating merchandise and applied sciences; future outcomes from our ongoing and deliberate medical trials; our skill to acquire satisfactory financing, together with by our financing facility with Oberland, to fund our deliberate medical trials and different bills; developments within the business; the authorized and regulatory framework for the business, together with the receipt and upkeep of clearances to conduct or proceed medical testing; future expenditures dangers associated to our asset-centric company mannequin; the chance that anybody or extra of our product candidates is not going to be efficiently developed and/or commercialized; the chance that the outcomes of preclinical research or medical research is not going to be predictive of future leads to reference to future research; geo-political dangers such because the Russia-Ukraine warfare and dangers associated to the continued COVID-19 pandemic together with the results of the Delta, Omicron and some other variants. These and different dangers regarding our packages and operations are described in extra element in our Quarterly Report on Kind 10-Q for the quarter ended March 31, 2022, and our different stories, that are on file with the U.S. Securities and Change Fee. We explicitly disclaim any obligation to replace any forward-looking statements besides to the extent required by legislation.


Kristen Okay. Sheppard, Esq.
SVP of Investor Relations